Baird downgraded Vor Bio (VOR) to Neutral from Outperform with a price target of 25c, down from $14, after the company announced plans to wind down its clinical and manufacturing operations, beginning immediately, and pivot to looking for strategic alternatives for the business. The update led Baird to downgrade the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: